Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A‐LONG study subjects with severe haemophilia A

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 23; no. 3; pp. 392 - 399
• Main Authors: Shapiro, A. D., Mahlangu, J. N., Perry, D., Pasi, J., Quon, D. V., Chowdary, P., Tsao, E., Li, S., Innes, A., Pierce, G. F., Allen, G. A.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.05.2017
• Subjects: Arm; Bleeding; Coagulation factors; factor VIII; Factor VIII - adverse effects; Factor VIII - pharmacokinetics; Factor VIII - therapeutic use; Factor VIII deficiency; Fc receptors; FDA approval; Female; Fusion protein; haemophilia A; Hemophilia; Hemophilia A - complications; Hemophilia A - prevention & control; Hemorrhage; Hemorrhage - complications; Hemorrhage - drug therapy; Humans; Immunoglobulin Fc Fragments - genetics; Male; phase 3; Prophylaxis; recombinant Fc fusion protein; Recombinant Fusion Proteins - adverse effects; Recombinant Fusion Proteins - pharmacokinetics; Recombinant Fusion Proteins - therapeutic use; Safety; Treatment Outcome; phase 3; bleeding; haemophilia A; factor VIII; prophylaxis; recombinant Fc fusion protein

Introduction The Phase 3 A‐LONG study demonstrated the safety and efficacy of rFVIIIFc for the control and prevention of bleeding episodes in severe haemophilia A. Aim To describe the treatment of bleeding episodes with rFVIIIFc in the A‐LONG study. Methods A‐LONG subjects (<1 IU dL−1 endogenous...